Puretech Health PLC with ticker (LON:PRTC) now has a potential upside of 51.7% according to Liberum Capital.
Liberum Capital set a target price of 580 GBX for the company, which when compared to the Puretech Health PLC share price of 280 GBX at opening today (09/12/2021) indicates a potential upside of 51.7%. Trading has ranged between 267 (52 week low) and 448 (52 week high) with an average of 135,549 shares exchanging hands daily. The market capitalisation at the time of writing is £815,814,571.
PureTech Health PLC is a clinical stage biotherapeutics company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The Company’s wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.